Although the KAI1/CD82 protein has been reported to inhibit cell metastasis in many studies, its mechanism of action has not yet been fully elucidated. In the present study, we investigated the possible effects of KAI1/CD82 on the metastatic phenotype in H1299 lung carcinoma cells. These studies were based on the pivotal role that the acquisition of motile phenotype plays on the initial steps of metastasis. KAI1/CD82-mediated morphological changes were observed using phase contrast microscopy. We report here, that a KAI1/CD82-induced phenotypic change was involved in the decrease of Rac1 expression and GTPase activity. However, we found that KAI1/CD82 did not regulate Rac1 mRNA levels. This suggests the existence of another regulatory mechanism of Rac1 protein maturation or activation. To identify the signaling pathway of Rac1 regulation, we investigated the PI3K/Akt/mTOR pathway, since the PI3K/Akt pathway regulates Rac1 activation and mTOR is known to play a regulatory role in protein translation. H1299/CD82-transfectants showed lower mTOR expression and cell growth than the control group. The data obtained from this study suggested that KAI1/CD82 decreased the metastatic phenotype of H1299 lung carcinoma cells by down-regulating Rac1 expression through the PI3K/Akt/mTOR pathway.

Altered physiologic and benign F-18 FDG uptake in the lower cervical muscle and chest wall following ipsilateral breast surgery or radiotherapy were common, and also normal physiologic uptake in ovary and uterus, brown fat, thyroid were considered as predominant findings in women patients with breast cancer. Knowledge of these findings might aid in the interpretation of FDG PET/CT in patients with breast cancer.

Complementary and Alternative Medicine (CAM) is widely used in modern society and is becoming a common method to reduce the adverse effect of orthodox medicine. Recently among CAM therapies, mind-body medicine is interested in cancer patients.Scientific methods which consist of replicability and sustainability are essential factor for modern medicine. Therefore, randomized clinical trial should be considered to advance CAM. Integrated medicine means all parts of medicine included with CAM

Background: This study was conducted to identify factors affecting perceived stress for cancer patients. Methods: A total of 104 cancer patients in a university hospital located in J province were participated. After IRB approval, the study period was between April and September, 2017, and the data were collected using by structured questionnaires. Collected data were analyzed by descriptive analysis, t-test, ANOVA, Pearson's correlation, and multiple regression using SPSS 22.0 statistical program. Results: The average score of uncertainty, resilience, and stress were 96.17, 88.54, and 17.76. As resilience, there were significant differences by spouse (t=−2.042, p=.044) and pain. As stress perceived, there were significant differences by spouse (t=−2.304, p=.023) and pain (t=2.097, p=.038). There were significantly positive correlations stress and uncertainty (r=.286, p=＜.001). In addition there were significantly negative correlation between stress resilience (r=−.287, p=.003). In this study factors affecting stress perceived were spouse (β=.337, p＜.001),resilience (β=−.335, p ＜.001), pain (β=.206, p=.023) and uncertainty (β=.204, p=.022). The factors explained 32% of perceived stress. Conclusions: Therefore, it is suggested that strategies of pain management and nursing intervention for strengthening emotional support including uncertainty and resilience management for cancer patients.

Purpose: Neoadjuvant chemotherapy (NAC) has become the standard treatment for locally advanced breast cancer. The postoperatively adjuvant systemic treatment is based on the status of the histological and biological markers of either the pre-NAC or the post-NAC. There have been several reports that have demonstrated the changes of the histological and biological markers after NAC. The aim of this study is to investigate the effects of NAC on the expression of the histological and biological markers of breast cancer. Methods: We analyzed the paired pre-and post-NAC tumor specimens from 37 patients with stage IIIA, IIIB or IIIC breast cancer. All the patients received 2 to 6 cycles of anthracycline-containing NAC. Over 6 pieces of pre-NAC tumor specimens were taken by 14 G core needle from multiple sites of a tumor, and the post-NAC specimens were taken at the time of the operation. The histologic grade and immunohistochemical expression of estrogen receptor (ER), progesterone receptor (PR), c-erbB2, p53, Ki67, CD31 and pglycoprotein were analyzed in the paired pre-and post-NAC tumor specimens from 37 patients. Results: Twenty five patients (67.6%) revealed significant changes of more than one marker. The markers that showed changes of more than two grades were as follows; histologic grade in 1, ER in 4, PR in 9, c-erbB2 in 4, p53 in 1, Ki67 in 4, CD31 in 9 and pglycoprotein in 5 patients. In 12 patients (32.4%), significant changes were found in the markers that can influence the decision-making for adjuvant treatment (i.e. ER, PR and cerbB2). The ER/PR status changed from positive to negative in 4 patients and c-erbB2 was changed from positive to negative in 3 patients. Among those patients, the strategy of adjuvant treatment was adjusted according to the changes. Conclusion: The specimens for the histologic and biologic markers of a tumor should be taken before NAC because NAC can have an influence on the expression of the prognostic markers of locally advanced breast cancers, and this may subsequently influence predicting the prognosis and making the decision for adjuvant systemic treatment.